Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study -

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
Information type: Randomised controlled trials
Source: Diabetes Care
Specialities: Diabetes
Summary
RCT (n=793) reported that sotagliflozin combined with optimized insulin therapy was associated with sustained HbA1c reduction at 24 weeks (placebo-adjusted HbA1c reductions 0.36% and 0.41% with sotagliflozin 200 and 400 mg, respectively).
UKMi comment
Sotagliflozin is a dual sodium-glucose co-transporter (SGLT) 1 / SGLT2 inhibitor, which acts by decreasing absorption and increasing urinary excretion of glucose. It has been filed in EU with launches expected to be in 2019 for type 1 diabetes, and in 2021 for type 2 diabetes.
Related links: